Medicament for liver regeneration and for treatment of liver failure
申请人:HELMHOLTZ-ZENTRUM FÜR INFEKTIONSFORSCHUNG GmbH
公开号:US10188682B2
公开(公告)日:2019-01-29
The present invention relates to the use of a compound which inhibits the activity of MKK4 as a medicament for the treatment of a patient suffering from an impaired liver function, to the use of a compound as a medicament for the treatment of liver failure, including acute/fulminant or chronic liver failure and/or for increasing the regeneration of liver tissue in a patient.
申请人:Helmholtz-Zentrum für Infektionsforschung GmbH
公开号:EP3192870B1
公开(公告)日:2018-10-17
MEDICAMENT FOR LIVER REGENERATION AND FOR TREATMENT OF LIVER FAILURE
申请人:Zender Lars
公开号:US20140141510A1
公开(公告)日:2014-05-22
The present invention relates to the use of a compound which inhibits the activity of MKK4 as a medicament for the treatment of a patient suffering from an impaired liver function, to the use of a compound as a medicament for the treatment of liver failure, including acute/fulminant or chronic liver failure and/or for increasing the regeneration of liver tissue in a patient.
US9186381B2
申请人:——
公开号:US9186381B2
公开(公告)日:2015-11-17
A Modular Approach to Triazole-Containing Chemical Inducers of Dimerisation for Yeast Three-Hybrid Screening
The yeast three-hybrid (Y3H) approach shows considerable promise for the unbiased identification of novel small molecule-protein interactions. In recent years, it has been successfully used to link a number of bioactive molecules to novel protein binding partners. However despite its potential importance as a protein target identification method, the Y3H technique has not yet been widely adopted, in part due to the challenges associated with the synthesis of the complex chemical inducers of dimerisation (CIDs). The development of a modular approach using potentially “off the shelf” synthetic components was achieved and allowed the synthesis of a family of four triazole-containing CIDs, MTX-Cmpd2.2-2.5. These CIDs were then compared using the Y3H approach with three of them giving a strong positive interaction with a known target of compound 2, TgCDPK1. These results showed that the modular nature of our synthetic strategy may help to overcome the challenges currently encountered with CID synthesis and should contribute to the Y3H approach reaching its full potential as an unbiased target identification strategy.